Intra-abdominal candidiasis: The importance of early source control and antifungal treatment

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Vergidis, Pascalis ^a   Clancy, Cornelius J ^a,b   Shields, Ryan K ^a   Park, Seo Young ^a   Wildfeuer, Brett N ^a   Simmons, Richard L ^a   Nguyen, M Hong ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIAL INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CHOLANGITIS; CHOLECYSTITIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONSULTATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; EARLY ANTIFUNGAL TREATMENT; EARLY INTERVENTION; EARLY SOURCE CONTROL; FEMALE; HUMAN; INCIDENCE; INFECTED PANCREATIC NECROSIS; INFECTION CONTROL; INFECTION RISK; INTRAABDOMINAL CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; MORTALITY; NONHUMAN; PANCREAS NECROSIS; PERITONITIS; PICHIA KUDRIAVZEVII; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; ABDOMINAL CAVITY; COINFECTION; DRUG EFFECTS; GASTROINTESTINAL TRACT; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ABDOMINAL ABSCESS; ABDOMINAL CAVITY; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; COINFECTION; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INTRAABDOMINAL INFECTIONS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONITIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84965116960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153247     Document Type: Article

References (40)

1. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013; 56(9):1284-92. doi: 10.1093/cid/cit006 PMID: 23315320.
2. Clancy CJ, Nguyen MH. Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev Anti Infect Ther. 2014; 12(7):731-4. doi: 10.1586/14787210.2014.919853 PMID: 24850393.
3. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med. 2013; 39(12):2092-106. doi: 10.1007/s00134-013-3109-3 PMID: 24105327.
4. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015; 373(15):1445-56. doi: 10.1056/NEJMra1315399 PMID: 26444731.
5. Blot SI, Vandewoude KH, De Waele JJ. Candida peritonitis. Curr Opin Crit Care. 2007; 13(2):195-9. PMID: 17327742.
6. Montravers P, Leroy O, Eckmann C. Intra-abdominal candidiasis: it's still a long way to get unquestionable data. Intensive Care Med. 2015; 41(9):1682-4. doi: 10.1007/s00134-015-3894-y PMID: 26088912.
7. Bassetti M, Righi E, Ansaldi F, Merelli M, Scarparo C, Antonelli M, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015. doi: 10.1007/s00134-015-3866-2 PMID: 26077063.
8. Rex JH. Candida in the peritoneum: passenger or pathogen? Crit Care Med. 2006; 34(3):902-3. PMID: 16505676.
9. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Critical Care Medicine. 2006; 34(3):646-52. WOS:000235587100009. PMID: 16505648
10. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39(2):165-228. doi: 10.1007/s00134-012-2769-8 PMID: 23361625.
11. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs. 2012; 72(6):e17-32. doi: 10.2165/11599800-000000000-00000 PMID: 22480338; PubMed Central PMCID: PMC3585770.
12. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003; 37(8):997-1005. doi: 10.1086/378702 PMID: 14523762.
13. Lamme B, Mahler CW, van Ruler O, Gouma DJ, Reitsma JB, Boermeester MA. Clinical predictors of ongoing infection in secondary peritonitis: systematic review. World J Surg. 2006; 30(12):2170-81. doi: 10.1007/s00268-005-0333-1 PMID: 17102920.
14. McLauchlan GJ, Anderson ID, Grant IS, Fearon KC. Outcome of patients with abdominal sepsis treated in an intensive care unit. Br J Surg. 1995; 82(4):524-9. PMID: 7613902.
15. Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse JP, et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg. 2002; 137(12):1341-6. PMID: 12470095.
16. Sandven P, Qvist H, Skovlund E, Giercksky KE, Group N, the Norwegian Yeast Study G. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med. 2002; 30(3):541-7. PMID: 11990912.
17. Alden SM, Frank E, Flancbaum L. Abdominal candidiasis in surgical patients. Am Surg. 1989; 55(1):45-9. PMID: 2913908.
18. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet. 1989; 2(8677):1437-40. PMID: 2574368.
19. Bayer AS, Blumenkrantz MJ, Montgomerie JZ, Galpin JE, Coburn JW, Guze LB. Candida peritonitis. Report of 22 cases and review of the English literature. Am J Med. 1976; 61(6):832-40. PMID: 1008070.
20. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery. 1980; 88(4):524-30. PMID: 7423375.
21. Kujath P, Lerch K. Secondary mycosis in surgery: treatment with fluconazole. Infection. 1989; 17(2):111-7. PMID: 2541084.
22. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999; 27(6):1066-72. PMID: 10397206.
23. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care. 2008; 12(1):204. doi: 10.1186/cc6212 PMID: 18279532; PubMed Central PMCID: PMC2374590.
24. Knitsch W, Vincent JL, Utzolino S, Francois B, Dinya T, Dimopoulos G, et al. A randomized, placebo-controlled trial of pre-emptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis. 2015. doi: 10.1093/cid/civ707 PMID: 26270686.
25. Lee SC, Fung CP, Chen HY, Li CT, Jwo SC, Hung YB, et al. Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect Dis. 2002; 44(1):23-7. PMID: 12376027.
26. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012; 18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039 PMID: 23137135.
27. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015. doi: 10.1093/cid/civ933 PMID: 26679628.
28. Edwards JE Jr., Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis. 1997; 25(1):43-59. PMID: 9243032.
29. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49(9):3640-5. doi: 10.1128/AAC.49.9.3640-3645.2005 PMID: 16127033; PubMed Central PMCID: PMCPMC1195428.
30. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006; 43(1):25-31. doi: 10.1086/504810 PMID: 16758414.
31. Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin Infect Dis. 2012; 54(8):1123-5. doi: 10.1093/cid/cis023 PMID: 22412062.
32. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012; 54(9):1240-8. doi: 10.1093/cid/cis200 PMID: 22431804.
33. Tissot F, Lamoth F, Hauser PM, Orasch C, Fluckiger U, Siegemund M, et al. β-Glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med. 2013; 188(9):1100-9. doi: 10.1164/rccm.201211-2069OC PMID: 23782027.
34. Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O, AmarCand study group. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011; 17(7):1061-7. doi: 10.1111/j.1469-0691.2010.03360.x PMID: 20825438.
35. Nguyen MH, Peacock JE Jr., Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100(6):617-23. PMID: 8678081.
36. Heisel T, Podgorski H, Staley CM, Knights D, Sadowsky MJ, Gale CA. Complementary amplicon-based genomic approaches for the study of fungal communities in humans. PLoS One. 2015; 10(2): e0116705. doi: 10.1371/journal.pone.0116705 PMID: 25706290; PubMed Central PMCID: PMC4338280.
37. Shields RK, Nguyen MH, Press EG, Clancy CJ. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother. 2014; 58(12):7601-5. doi: 10.1128/AAC.04134-14 PMID: 25288081; PubMed Central PMCID: PMC4249510.
38. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009; 37(5):1612-8. PMID: 19325476.
39. Cheng S, Clancy CJ, Xu W, Schneider F, Hao B, Mitchell AP, et al. Profiling of Candida albicans gene expression during intra-abdominal candidiasis identifies biologic processes involved in pathogenesis. J Infect Dis. 2013; 208(9):1529-37. doi: 10.1093/infdis/jit335 PMID: 24006479; PubMed Central PMCID: PMC3789567.
40. Cheng S, Clancy CJ, Hartman DJ, Hao B, Nguyen MH. Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. Infect Immun. 2014; 82(7):3015-22. doi: 10.1128/IAI.00062-14 PMID: 24799629; PubMed Central PMCID: PMC4097615.